Our Neurology 2020 paper titled "Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study" explores the cascades of  changes of several well-known Alzheimer disease (AD) markers including cerebrow spinal fluid (CSF), imaging (PET-PIB and MRI) and cognitive markers in cognitively normal participants. The baseline marker data of participants is modeled as a piecewise linear function of baseline age allowing one change point, without and with adjustment for covariates.  The change point of a marker incicates the acceleration time of point after which a greater percentage of the participants present preclinical AD compared to before the change point. Cosnistent with previous research, the study confirmed that Abeta42 showed the earliest change-point around 50 years old and cognition had a late change point around 62. The study further found Tau, pTau and MRI hippalcampal volume had their change point closer to cognition. We identified change points in all participants, as well as by stratification of APOE4 status. The data here displays the Supplemental table Table e-1 accompanying the paper where the change point results by stratification of APOE4 status are presented.

The baseline marker data of participants is modeled as a piecewise linear function of baseline age allowing one change point. We identified the change points in the AD markers among all the participants, and then by stratification of APOE4 status. The change points in all participants are consistent with those identified in the APOE4 negative subset.

The data here presents the Supplemental table Table e-1 accompanying the paper where we identified change points by stratification of APOE4 status.